title: [New Developments in CKD-MBD. Efficacy and safety of antiosteoporotic agents in CKD].
abstract: The risk of fragility fracture is considerably high among patients with chronic kidney disease. The drugs that reduce the risk of fragility fracture are anti-osteoporotic agents. Recently, many newly developed anti-osteoporotic agents have become available at bedside and now we have much more choices. We must be careful to use them appropriately for those with chronic kidney disease because some of them are contraindication for this disease condition.
authors.affiliation: Division of Blood Purification Therapy, Niigata University Medical and Dental Hospital, Japan.
authors.forename: Junichiro James
authors.initials: JJ
authors.lastname: Kazama
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology*; D050723:Fractures, Bone / Q000188:drug therapy*; D006801:Humans; D058866:Osteoporotic Fractures / Q000188:drug therapy*; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications*
chemical_list: D050071:Bone Density Conservation Agents